Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Mepron Articles

GSK offers extra cut-price drugs to more customers, incl NGOs, employers,

13 June 2001

GW's anti-HIV drug Trizivir backed in EU

18 July 2000

GW pipeline update reveals few drop-outs and steady progress

8 July 1999

First Market Launches For GW's Malarone

26 November 1997

Glaxo Wellcome 1996 Product Performance

17 March 1997

Dutch Government Reimbursement Blacklist Rises To 35

9 December 1996

Antivirals "Now 9% Of Anti-Infectives Market"

11 March 1996

US Drug Lag Does Not Exist, Claims FDA Study

15 January 1996

Glaxo Wellcome Unveils Revamped Pipeline

20 November 1995

Glaxo Wellcome Revamps R&D To Treble Productivity

13 November 1995

Burroughs Wellcome

22 May 1995

NICHE MARKETING IN THE BIOTECH INDUSTRY

26 July 1993

ATOVAQUONE VERSUS CO-TRIMOXAZOLE

31 May 1993

WELLCOME REFOCUSING R&D EFFORTS

10 May 1993

DRUG FIRMS TO WORK TOGETHER ON AIDS R&D

26 April 1993

WELLCOME INTERIMS DRIVEN BY ZOVIRAX

29 March 1993

NEW CHEMICAL ENTITIES LAUNCHED IN 1992

1 February 1993

FDA APPROVES 26 NEWDRUGS IN 1992

25 January 1993

COMPARATIVE TRIALS OF PCP DRUGS

18 January 1993

USA APPROVES WELLCOME DRUG FOR PCP

7 December 1992

DRUG COMPANIES FAILING TO TARGET MALARIA?

9 November 1992

WELLCOME PRETAX PROFITS RISE 25%

2 November 1992

PANEL BACKS TWO AIDS DRUGS IN USA

5 October 1992

EUROPE STOCK COMMENT

7 September 1992

ACUVEL ALTERNATIVE FOR PCP TREATMENT?

15 June 1992

Showing 1-25 of 25 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS